These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34373933)

  • 1. Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis.
    Tan C; Luo X; Li S; Yi L; Zeng X; Peng L; Qin S; Wang L; Wan X
    Clin Rheumatol; 2022 Jan; 41(1):63-73. PubMed ID: 34373933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.
    Prawjaeng J; Leelahavarong P; Budtarad N; Pilasant S; Chanjam C; Katchamart W; Narongroeknawin P; Kitumnuaypong T
    BMC Health Serv Res; 2023 May; 23(1):561. PubMed ID: 37259090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure.
    Li S; Li J; Peng L; Li Y; Wan X
    Rheumatol Ther; 2021 Jun; 8(2):775-791. PubMed ID: 33772743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia.
    Al-Abdulkarim H; Sharma Y; Attar SM; Husain W; Al-Homood I; Al Omari B; Mohamed O; Alsaqa'aby M; Jaheen AM; Anwar A; Hamad TM; Alzahrani Z
    J Med Econ; 2024; 27(1):134-144. PubMed ID: 38163926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population.
    Tan C; Li S; Yi L; Zeng X; Peng L; Qin S; Wang L; Wan X
    Adv Ther; 2021 May; 38(5):2571-2585. PubMed ID: 33837917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France.
    Ghabri S; Binard A; Pers YM; Maunoury F; Caro JJ
    Value Health; 2020 Apr; 23(4):461-470. PubMed ID: 32327163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China.
    Tian L; Xiong X; Guo Q; Chen Y; Wang L; Dong P; Ma A
    Pharmacoeconomics; 2020 Dec; 38(12):1345-1358. PubMed ID: 32929677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis.
    Peng K; Chan SCW; Wang Y; Cheng FWT; Yeung WWY; Jiao Y; Chan EWY; Wong ICK; Lau CS; Li X
    JAMA Netw Open; 2024 Jun; 7(6):e2418800. PubMed ID: 38922614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
    Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
    J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Archer R; Stevens JW; Goka E; Clowes M; Scott DL; Young A
    Pharmacoeconomics; 2017 Nov; 35(11):1141-1151. PubMed ID: 28550592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.
    Alemao E; Johal S; Al MJ; Rutten-van Mölken M
    Value Health; 2018 Feb; 21(2):193-202. PubMed ID: 29477401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.
    Tanaka E; Inoue E; Yamaguchi R; Shimizu Y; Kobayashi A; Sugimoto N; Hoshi D; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2017 Mar; 27(2):227-236. PubMed ID: 27472516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug.
    Kielhorn A; Porter D; Diamantopoulos A; Lewis G
    Curr Med Res Opin; 2008 Sep; 24(9):2639-50. PubMed ID: 18687164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.